Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. UCB Canada Inc. News release: Health Canada approves Cimzia (certolizumab pegol) for moderate to severe psoriasis. 2019 Mar 25.
  2. National Institute for Health and Care Excellence. Guidance: Certolizumab pegol for treating moderate to severe plaque psoriasis. 2019 Apr 17.

Related Articles